Quick Contact
- giovanni.loriga@cnr.it
- 0792841251
Giovanni Loriga
Experience & Activities
1998 Master’s degree in Chemistry – University of Sassari (Italy).
2006 PhD Degree in Pharmaceutical Sciences (XVIII Cycle) – University of Genova (Italy).
1999/2002 Temporary research fellow at Neuroscienze Scarl, Pula (CA) (Italy).
2007/2011 Temporary research fellow at National Research Council (CNR), Biomedical Technologies Institute (ITB), Pula (CA) (Italy).
2011/2018 Researcher at National Research Council (CNR), Traslational Pharmacology Institute (IFT), Pula (CA) (Italy).
2012/2014 Head of NMR and Bioanalytical Technologies Platform, Pula (CA) (Italy).
2018/ongoing Researcher at National Research Council (CNR), Biomolecular Chemistry Institute (ICB), Sassari (Italy).
Teaching and tutoring:
2001/2017 Relator of several degree thesis in Pharmacy and Chemistry and Pharmaceutical Technology, Department of Pharmacy, University of Sassari (Italy).
2001/2007 Courses and seminars teacher, Department of Pharmacy, University of Sassari (Italy).
Research works:
Structure-activity relationships (SAR) study of potential antitumoral agents and analgesic compounds.
Preparation of compounds with potential biological activity. Design and synthesis of:
– central nervous system (CNS) active molecules: compounds active on opioid (μ, δ, and κ), cannabinoid (CB1 and CB2), and nicotinic receptors (α4β2);
– caspase’s inhibitors with potential application against immune and inflammatory disorders;
– “Proteolysis Targeting Chimeras” (PROTACs) as new antiviral agents.
Asymmetric synthesis
Drug discovery
Structure-activity relationships (SAR)
Caspase inhibitors
Proteolysis Targeting Chimeras” (PROTACs)
Central nervous system active compounds
Opioids and cannabinoids
- F. Ulgheri, P. Spanu, F. Deligia, G. Loriga, M. P. Fuggetta, I. de Haan, A. Chandgudge, M. Groves, A. Domling. Design, synthesis and biological evaluation of 1,5-disubstituted α-amino tetrazole derivatives as non-covalent inflammasome-caspase-1 complex inhibitors with potential application against immune and inflammatory disorders. Eur. J. Med. Chem. 2022, 229, 114002. doi:10.1016/j.ejmech.2021.114002
- G. Loriga, P. Lazzari, I. Manca, S. Ruiu, M. Falzoi, G. Murineddu, M. E. H. Bottazzi, G. Pinna, G. A. Pinna. Novel diazabicycloalkane delta opioid agonists. Bioorg. Med. Chem. 2015, 23(17), 5527-5538. doi:10.1016/j.bmc.2015.07.036
- G. Loriga, P. Lazzari, S. Ruiu, G. Marchese, I. Manca, G. L. Casu, C. Dessì, G. A. Pinna, B. Asproni, G. Murineddu. Synthesis and biological evaluation of novel delta () opioid receptor ligands with diazatricyclodecane skeletons. Eur. J. Med. Chem. 2013, 69, 413-426. doi:10.1016/j.ejmech.2013.09.014
- G. Murineddu, P. Lazzari, S. Ruiu, A. Sanna, G. Loriga, I. Manca, M. Falzoi, C. Dessì, M. M. Curzu, G. Chelucci, L. Pani, G. A. Pinna. Tricyclic Pyrazoles. 4. Synthesis and Biological Evaluation of Analogues of the Robust and Selective CB2 Cannabinoid Ligand 1-(2′,4′-dichlorophenyl)-6-methyl-N-piperidin-1-yl-1,4-dihydroindeno[1,2-c]pyrazole-3-carboxamide. J. Med. Chem. 2006, 49(25), 7502-7512. doi:10.1021/jm060920
- G. Loriga, I. Manca, G. Murineddu, G. Chelucci, S. Villa, S. Gessi, L. Toma, G. Cignarella, G. A. Pinna. Synthesis of 3,6-diazabicyclo[3.1.1]heptanes as novel ligands for the opioid receptors. Bioorg. Med. Chem. 2006, 14(3), 676-691. doi:10.1016/j.bmc.2005.09.045
RESEARCH SITE OF SASSARI
giovanni.loriga@cnr.it
(+39) 0792841251
